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Effective and safe drug administration should be based on
knowledge that integrates the evolving physiological charac-
teristics of the individual patient who will receive the drug
with the pharmacokinetics (PK) and pharmacodynamics
(PD) of the prescribed drug. Consequently, clinical pharma-
cology in neonates and pregnant women is as dynamic and
diverse as the specific populations considered [1, 2]. Despite
this diversity, there is currently little integration of available
knowledge to guide and optimize pharmacotherapy in these
populations [3–6].
Mothers are commonly exposed to drugs during preg-
nancy, at delivery, or in the postpartum period, and this
includes women with preexisting comorbidities. Despite
this, dosing regimens are still commonly extrapolated from
regimens initially validated in adults and do not consider
the pregnancy related changes in physiology nor issues
related to fetal effects before or breastfeeding related exposure
after delivery [1, 6]. The same holds true for neonates.
The most obvious covariates in neonates relate to growth
and development, reflected and quantified by birth weight,
current weight, or age—either postnatal, gestational, or post-
menstrual age. There is already at least one log order of
variability in weight (<0.5 up to 5 kg) while both the height
velocity rate (10–20 cm/year) and the increase in body weight
(50% increase in the first 6 weeks) reflect the dynamics of
a rapidly evolving biological system during perinatal life.
The maturation related variability is further aggravated by
interfering disease characteristics (e.g., renal failure, sepsis,
and growth restriction) or treatmentmodalities (e.g., comed-
ication, extracorporeal membrane oxygenation, and whole
body cooling).
Since infants and pregnant women warrant a focused
approach due to the physiological changes related to matu-
ration (fetus, newborn) or pregnancy, understanding these
changes to predict exposure/effects is necessary. Modelling
emerged as a promising tool to improve prediction of
exposure/effects [3, 4, 6]. However, these methods need
further validation before this approach can be implemented.
In addition, both effects and side effects may be popula-
tion specific. This necessitates the validation of biomarkers
(e.g., liver enzymes, renal biomarkers, and blood pressure)
commonly applied in other populations or exploration to
develop, evaluate, and validate new approaches to assess drug
effect or side effects (PD) in infants or pregnant women that
are valid and appropriate for clinical use. Finally, practices
and clinical care also evolve. Mothers undergo surgical
interventions during pregnancy to improve fetal outcome,
while hypothermia to improve neurodevelopment outcome
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in term neonates or trends in respiratory support in preterm
neonates affect pharmacotherapy during neonatal intensive
care [1–6]. The different topics discussed in this special issue
on perinatal pharmacology cover the broad field of perinatal
pharmacology.
This includes animal experimental studies describing
zonisamide pharmacokinetics in the pregnant rabbit and
the impact of alfa-7 nicotinic receptor modulation on brain
inflammation in a neonatal asphyxia model in mice. Such
specific studies may support the subsequent development of
new dosing and treatment strategies in human populations.
This is of clinical relevance since both perinatal epileptic
syndromes and perinatal asphyxia still suffer from poor long
term outcome.
As mentioned earlier, off-label use of drugs is unfortu-
nately common practice, even for population specific clinical
syndromes like pregnancy related nausea or vomiting, i.c.
hyperemesis of pregnancy, a common medical condition
in pregnancy. There is an increasing trend to prescribe
ondansetron, although the safety of ondansetron for use in
human pregnancy has not been established. In the absence of
prospective evaluation of such drugs, retrospective analysis
of safety and tolerance data may provide caregivers with
information on the presence and the extent of such adverse
effects.This strategy and its limitations have been explored in
a dataset on ondansetron exposure in 251 pregnant women
from Western Australia. Off-label indications can also be
explored on its effectiveness, as illustrated for prevention of
preterm delivery following folic acid supplementation. It is
well known that folic acid supplementation is recommended
in the periconceptional period to prevent neural tube defects.
Due to the involvement of folic acid in a number of cellular
processes, other pregnancy outcomes such as miscarriage,
recurrentmiscarriage, low birthweight, preeclampsia, abrup-
tio placentae, stillbirth, and preterm birth have also been
investigated in an off-label setting. For the prevention of
preterm birth, E. Mantovani et al. describe a discrepancy
between the slight decreases in pretermbirth in observational
studies, a finding not consistent with the results of ran-
domized controlled trials. At least these contrasting findings
reillustrate the need to perform randomized controlled trials
in this specific population.
During the study design and dose selection, population
tailored pharmacokineticmodelling can be applied to predict
the exposure/effect relationship, but these models need vali-
dation and optimization [3, 6]. The paper of J. G. C. van Has-
selt et al. on cefazolin pharmacokinetics during pregnancy
explores the feasibility to integrate the known physiological
changes related to pregnancy (i.c. glomerular filtration rate,
protein binding) to predict changes in cefazolin disposition
during pregnancy.The authors compared a semiphysiological
versus an empirical modelling in an attempt to further
validate their semiphysiological model. Following validation,
such semiphysiological models can subsequently be applied
to other compounds that undergo the same elimination
routes.
Two of the papers focus on aspects of neonatal clin-
ical pharmacology. The integration of pharmacogenetics
into perinatal pharmacology is complex, since it is related
to ontogeny or phenotypic activity during pregnancy. To
illustrate this, the impact of cytochrome P450 (CYP) 2D6
polymorphisms in part depends on the postmenstrual
age at exposure [7]. Recently, a link between neonatal
pharmacogenetics (i.c. 𝜇-opioid receptor and catechol-O-
methyltransferase single-nucleotide polymorphisms) and the
presence and extent of neonatal abstinence syndrome fol-
lowing maternal opioid exposure has been documented [8].
In this special issue, the potential link between pharma-
cogenetics and the use of Serotonin Reuptake Inhibitors
(SSRIs) during pregnancy and adverse neonatal outcome was
explored. Finally, the impact of pharmacological strategies to
facilitate endotracheal intubation following the introduction
of the INSURE, that is, intubation-surfactant administration-
extubation strategy in preterm neonates, is discussed. It is a
nice illustration of the need to reconsider our pharmacologi-
cal strategies once the outcome variables (i.c. shorter duration
of analgosedation) change.
We are aware that the topics discussed are indeed very
heterogeneous. This was however the primary aim of this
special issue, since progress in perinatal pharmacology will
only be possible when different types of research expertise,
including but not limited to clinical researchers, (pharmaco)
geneticists, PK/PD modellers, or researchers with an animal
experimental background, collaborate with the common
goal to improve pharmacotherapy in pregnant women and
their infants. We aspire that this special issue will stimulate
clinicians and clinician-scientists to collaborate as multidis-
ciplinary teams to achieve this goal.
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